Wayground logo

Free Printable Worksheets

Font size

S
M
L
XL
Worksheets

GYAN- GROW YOUR APTITUDE NATURALLY

Total questions: 12

Worksheet time: 9mins

Name
Class
Date
1.

As per Sept Priority what is the Azmarda/metolar tl Rx objective

a)

30/50

b)

50/30

c)

40/50

d)

50/40

2.

which are the two brands need to be detailed to card and phy as per Sept priority

a)

Metolar xr/Metolar TL

b)

Azmarda/Metolar TL

c)

Metolar TL/Metolar AM

d)

Carloc/Metolar AM

3.

Doctor, suffering _______________________________

___________________________ a strong protection that shields them from further damage

a)

from a heart ailment takes a lot away from your patients. Such patients need

b)

from a heart condition takes a lot away from your patients. Such patients need

c)

from a heart disease takes a lot from my patients. Such patients need

d)

from a heart condition takes a lot more away from your patients. Such patients require

4.

How much is the BP reduction at the end of 12 weeks with Metoprolol extended release and amlodipine(Metolar AM)

a)

20/10

b)

15/22

c)

25/15

d)

24/12

5.

As per the__________________, Telmisartan in Metolar TL has comparative effectiveness to Ramipril in reducing incidence

a)

INTERHEART TRIAL

b)

CARDS TRIAL

c)

IDEAL TRIAL

d)

ON TARGET TRIAL

6.

Metolar TL improves ___________________ in ____________________________

a)

insulin sensitivity , angina patients with diabetes

b)

heart failure, angina patients with ACS

c)

insulin sensitivity, hypertensive with diabetes

d)

insulin sensitivity, heart failure patients with angina

7.

Metolar TL shields against ________________________________

a)

ischemic recurrence in stable IHD

b)

ischemic episodes in stable IHD

c)

ischemic episodes in MI

d)

ischemic episodes in hypertension

8.

Metolar TL shows reduced number and duration of ischemic episodes compared to ______________

a)

diltiazem 60 mg

b)

Amlodipin 5 mg

c)

Olmisartan 40 mg

d)

Ramipril 5 mg

9.

as per the SHIft trial, there is_________________ in hospitalization for worsening heart failure with Ivabradine

a)

20% reduction

b)

22% reduction

c)

24% increment

d)

26% reduction

10.

as per the SHIft trial, Ivabradin shows ________________ in CV death and hospitalization for worsening heart failure

a)

18% reduction

b)

18% increment

c)

29% reduction

d)

26% reduction

11.

What is the indication of PLETOZ

a)

management of intermittent subjugation

b)

management of Intermittent claudication

c)

management of peripheral vascular lesion

d)

management of Berger's Disease

12.

Dosage of Pletoz is

a)

100/50 mg od 1 hour before food or 2 hours after food

b)

100/50 mg bid before food or 2 hours after food

c)

100/50 mg tid 2 hours after food

d)

100/50 mg qid 2 hoursbefore food or 2 hours after food